BAMS
CLDX icon

Bellevue Asset Management (Switzerland)’s Celldex Therapeutics CLDX Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$2.51M Hold
10,667
– – 0.38% 75
2015
Q3 		$1.69M Buy
10,667
+5,734
+116% +$1.62M 0.28% 91
2015
Q2 		$1.87M Sell
4,933
-2,000
-29% -$794K 0.26% 87
2015
Q1 		$2.61M Buy
+6,933
New +$2.48M 0.36% 69

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s CLDX Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) held its Celldex Therapeutics (CLDX) position steady in Q4 2015 at 10,667 shares worth $2.51M. The position accounts for 0.38% of the portfolio, ranked #75.

Bellevue Asset Management (Switzerland) first reported a position in CLDX in Q1 2015 and has held it in 4 quarters since. The position peaked at $2.61M in Q1 2015. 171 funds tracked by Wall St. Rank hold CLDX as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 10,667 shares of Celldex Therapeutics worth $2.51M as of Q4 2015.
  • Bellevue Asset Management (Switzerland) left its Celldex Therapeutics share count unchanged in Q4 2015.
  • Celldex Therapeutics made up 0.38% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #75 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Celldex Therapeutics in Q1 2015 and has held it in 4 quarters since.
  • Bellevue Asset Management (Switzerland)'s Celldex Therapeutics position peaked at $2.61M in Q1 2015.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.